Results 201 to 210 of about 28,958 (244)

The Antithrombotic Effect of Dabigatran

Canadian Journal of Cardiology, 2014
A 72-year-old man presented to the emergency department because of a sudden onset of left-sidedweakness. The patient had his first cerebral vascular accident at the age of 49 years. Atrial fibrillation (AF) and hypertension were diagnosed at that time.
Chao-Lin, Lee, Hsueh-Han, Wang, Hsuan-Ming, Tsao   +2 more
openaire   +2 more sources

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire   +2 more sources

Dabigatran, bleeding, and the regulators

BMJ, 2014
Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of ...
Thomas J, Moore, Michael R, Cohen, Donald R, Mattison   +2 more
openaire   +2 more sources

Idarucizumab for dabigatran overdose

Clinical Toxicology, 2016
An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Marijke, Peetermans, Charles, Pollack, Paul, Reilly, Laurens, Liesenborghs, Marc, Jacquemin, Jerrold H, Levy, Jeffrey I, Weitz, Peter, Verhamme   +7 more
openaire   +2 more sources

Dabigatran in Clinical Practice

Clinical Therapeutics, 2012
Stroke and systemic thromboembolism remain critical causes of mortality and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. Randomized clinical data demonstrate dabigatran to be
Rangadham, Nagarakanti, Christopher R, Ellis   +1 more
openaire   +2 more sources

Pros and cons of dabigatran

American Journal of Health-System Pharmacy, 2011
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Christine M, Cheng, Megan R, McCurdy, Heather A, Wong, Steven R, Kayser   +3 more
openaire   +2 more sources

Dabigatran-Induced Esophagitis

Clinical Gastroenterology and Hepatology, 2014
We report 2 cases of drug-induced esophagitis associated with dabigatran, a new oral anticoagulant. Both patients were prescribed dabigatran at 110 mg twice daily for atrial fibrillation as an alternative to warfarin. The first case was a 70-year-old man who had been taking dabigatran for 14 days and was referred to our hospital because of retrosternal
Akifumi, Ootani, Yoshihiro, Hayashi, Yugo, Miyagi   +2 more
openaire   +2 more sources

Dabigatran/Dabigatran etexilate

Drugs of the Future, 2005
null Sorbera, L.A., null Bozzo, J., null Castaner, J.   +2 more
openaire   +1 more source

Dabigatran

Practical Diabetes, 2012
Liesl Currie, Gerry McKay, Miles Fisher
openaire   +1 more source

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

Thrombosis and Haemostasis, 2010
J. Ryn, J. Stangier, S. Haertter, Karl‐Heinz Liesenfeld, W. Wienen, M. Feuring, A. Clemens   +6 more
semanticscholar   +1 more source